SCHEMBL1787046

SCHEMBL1787046

CCOC(=O)Cc1ccc2c(c1)CCN(C1=CC=C1)CC2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPE Q05469 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
ALDH1A1 P00352 3/20 0.36
NOTUM Q6P988 1/20 0.36
LMNA P02545 1/20 0.36
HTR1A P08908 1/20 0.36
CHRM5 P08912 1/20 0.36
SLC6A2 P23975 1/20 0.36
HRH2 P25021 1/20 0.36
ADRA1D P25100 1/20 0.36
HTR1B P28222 1/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
HTR1E P28566 1/20 0.36
HRH1 P35367 1/20 0.36
HTR2B P41595 1/20 0.36
SLC6A3 Q01959 1/20 0.36
TMEM97 Q5BJF2 1/20 0.36
SIGMAR1 Q99720 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31478141 0.82 LMNA (0.46) LIPEALDH1A1LMNANPC1PKM
SCHEMBL1789593 0.81 ALDH1A1 (0.43) MEN1KMT2AALDH1A1LMNASMN1; SMN2
Potassium Ion SCHEMBL1787642 0.81 ALDH1A1 (0.34) MEN1KMT2AALDH1A1LMNASMN1; SMN2
SCHEMBL1790557 0.81 ALDH1A1 (0.37) MEN1KMT2AALDH1A1LMNASMN1; SMN2
SCHEMBL1790111 0.76 GRIN2B (0.39) ADRA1DHTR2AHTR2CHTR2BGRIN2D
SCHEMBL1787043 0.76 HRH3 (0.48) HRH1POLB
SCHEMBL1790034 0.76 LMNA (0.41) LMNASMN1; SMN2MAPTTP53POLB
SCHEMBL1786585 0.76 HPGD (0.46) ALDH1A1LMNASMN1; SMN2MAPT
SCHEMBL1790805 0.75 KMT2A (0.53) KMT2AALDH1A1SMN1; SMN2L3MBTL1GAA
SCHEMBL1787830 0.75 PRMT5 (0.37) SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2326625-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS Takeda Pharmaceutical Company Limited (JP) 2011-06-01 EP disclosed
US-20110124626-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-26 US disclosed
WO-2010007382-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED. (JP) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124626-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS HRH4, HRH3, HRH2 LIPE 3416/4885MEN1 2515/4885KMT2A 731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.